Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis-Reference-Cited by-同舟云学术

Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis

Published:2009-09 Issue:5 Volume:10 Page:564-575
ISSN:1467-7881
Container-title:Obesity Reviews
language:en
Short-container-title:

Author:

Johansson K.,Neovius K.,DeSantis S. M.,Rössner S.,Neovius M.

Publisher

Wiley

Subject

Public Health, Environmental and Occupational Health,Endocrinology, Diabetes and Metabolism

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1467-789X.2009.00581.x/fullpdf

Reference49 articles.

1. 1. Curioni C , Andre C . Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006; CD006162.

2. 2. Padwal R , Li SK , Lau DC . Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004; CD004094.

3. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials;Christensen;Lancet,2007

4. Drug treatments for obesity: orlistat, sibutramine, and rimonabant;Padwal;Lancet,2007

5. 5. FDA Advisory Committee. FDA Briefing Document. NDA 21-888. Zimulti (rimonabant). Advisory Committee - June 13, 2007. [WWW document]. URL http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-fda-backgrounder.pdf (accessed September 2007).

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Negative allosteric modulation of CB1 cannabinoid receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception;Neuropharmacology;2024-10

2. A head-to-head comparison of MM/PBSA and MM/GBSA in predicting binding affinities for the CB1 cannabinoid ligands;2024-06-25

3. An Innovative Mei-Gin Formula Exerts Anti-Adipogenic and Anti-Obesity Effects in 3T3-L1 Adipocyte and High-Fat Diet-Induced Obese Rats;Foods;2023-02-23

4. Negative allosteric modulation of CB1 cannabinoid receptor signaling suppresses opioid-mediated reward;Pharmacological Research;2022-11

5. A Retrospective Analysis of the Effectiveness of Taking <italic>Gambi-tang</italic> in Overweight and Obese Adults;The Journal of Internal Korean Medicine;2022-06-30